In this ESC 2025 CardioNerds discussion, CardioNerds Fellows Drs. Georgia Vasilakis Tsatiris and Anna Radhakrishnan interview Dr. Kevin Alexander, Assistant Professor of Cardiovascular Medicine at Stanford, about the latest findings from the ATTRibute-CM trial. Dr. Alexander, an expert in cardiac amyloidosis, explains that the phase 3 trial evaluated the efficacy of Acoramidis—a highly selective Transthyretin stabilizer—in patients with wild-type or hereditary ATTR-CM, showing significant benefits in cardiovascular outcomes.
Advertisement
PVR severity is linked to higher short-term mortality in HFrEF, highlighting its role in risk stratification.
IMPLEMENT-HF raised heart failure quad therapy use from 4.7% to 44.6% at discharge and 0% to 44.8% at 30 days.
Dr. Salman Allana shares key insights on how operator volume impacts retrograde CTO PCI success and outcomes.
Routine health screenings may not reduce death risk, study finds—though early detection remains key.
Experts call for better trials and teamwork to advance transcatheter valve treatment for heart failure-related valve disease.
CTA-first screening before TAVR avoids invasive angiography in 53% of patients—without compromising outcomes.
Expert Interviews on Cardiology
Cardio Care Today News delivers the latest medical industry news, giving healthcare professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.